Elisabet CuyÃ s

List of Publications by Year
in descending order

77 papers	2,738 citations	147801 31 h-index	206112 48 g-index
78 all docs	78 docs citations	78 times ranked	4946 citing authors

#	Article	IF	Citations
1	The Warburg effect version 2.0: Metabolic reprogramming of cancer stem cells. Cell Cycle, 2013, 12, 1166-1179.	2.6	146
2	Cell Cycle Regulation by the Nutrient-Sensing Mammalian Target of Rapamycin (mTOR) Pathway. Methods in Molecular Biology, 2014, 1170, 113-144.	0.9	108
3	Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity. Aging, 2020, 12, 8-34.	3.1	99
4	The anti-malarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer. Scientific Reports, 2013, 3, 2469.	3.3	97
5	Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells. Oncotarget, 2014, 5, 8306-8316.	1.8	94
6	Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway. Cell Cycle, 2013, 12, 3109-3124.	2.6	90
7	Metformin Is a Direct SIRT1-Activating Compound: Computational Modeling and Experimental Validation. Frontiers in Endocrinology, 2018, 9, 657.	3.5	85
8	IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. Scientific Reports, 2013, 3, 2560.	3.3	74
9	Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy. OncoImmunology, 2019, 8, e1633235.	4.6	70
10	Mitophagy-driven mitochondrial rejuvenation regulates stem cell fate. Aging, 2016, 8, 1330-1352.	3.1	70
11	Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo. Scientific Reports, 2013, 3, 2459.	3.3	67
12	Stem cell-like ALDH^{bright}cellular states in EGFR-mutant non-small cell lung cancer: A novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin. Cell Cycle, 2013, 12, 3390-3404.	2.6	65
13	The nutritional phenome of EMT-induced cancer stem-like cells. Oncotarget, 2014, 5, 3970-3982.	1.8	61
14	Metformin directly targets the H3K27me3 demethylase KDM6A/UTX. Aging Cell, 2018, 17, e12772.	6.7	58
15	Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile. Cell Cycle, 2014, 13, 1132-1144.	2.6	57
16	Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells. Food and Chemical Toxicology, 2013, 60, 360-368.	3.6	53
17	Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells. Carcinogenesis, 2018, 39, 601-613.	2.8	53
18	Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. Oncotarget, 2015, 6, 12279-12296.	1.8	53

#	Article	IF	Citations
19	Silibinin is a direct inhibitor of STAT3. Food and Chemical Toxicology, 2018, 116, 161-172.	3.6	52
20	The Consequences of 3,4-Methylenedioxymethamphetamine Induced CYP2D6 Inhibition in Humans. Journal of Clinical Psychopharmacology, 2008, 28, 523-529.	1.4	49
21	STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer. Cell Cycle, 2016, 15, 3413-3418.	2.6	49
22	Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin. Oncotarget, 2016, 7, 32006-32014.	1.8	47
23	Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer. Histology and Histopathology, 2017, 32, 687-698.	0.7	40
24	Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment. Oncotarget, 2014, 5, 2344-2348.	1.8	40
25	Suppression of endogenous lipogenesis induces reversion of the malignant phenotype and normalized differentiation in breast cancer. Oncotarget, 2016, 7, 71151-71168.	1.8	40
26	The Influence of Genetic and Environmental Factors among MDMA Users in Cognitive Performance. PLoS ONE, 2011, 6, e27206.	2.5	38
27	The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes. Aging, 2020, 12, 4794-4814.	3.1	38
28	Reprogramming of non-genomic estrogen signaling by the stemness factor SOX2 enhances the tumor-initiating capacity of breast cancer cells. Cell Cycle, 2013, 12, 3471-3477.	2.6	37
29	Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas. Oncotarget, 2015, 6, 32317-32338.	1.8	35
30	Exploring the Process of Energy Generation in Pathophysiology by Targeted Metabolomics: Performance of a Simple and Quantitative Method. Journal of the American Society for Mass Spectrometry, 2016, 27, 168-177.	2.8	35
31	Oncometabolic Nuclear Reprogramming of Cancer Stemness. Stem Cell Reports, 2016, 6, 273-283.	4.8	34
32	Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells. Cell Death and Disease, 2021, 12, 977.	6.3	33
33	Intestinal Permeability Study of Clinically Relevant Formulations of Silibinin in Caco-2 Cell Monolayers. International Journal of Molecular Sciences, 2019, 20, 1606.	4.1	32
34	GENETIC STUDY: 5â€HTTLPR polymorphism, mood disorders and MDMA use in a 3â€year followâ€up study. Addiction Biology, 2010, 15, 15-22.	2.6	31
35	Metabostemness: Metaboloepigenetic reprogramming of cancer stem-cell functions. Oncoscience, 2014, 1, 803-806.	2.2	31
36	Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin. Oncotarget, 2013, 4, 1484-1495.	1.8	31

#	Article	IF	Citations
37	Neurotoxic Thioether Adducts of 3,4-Methylenedioxymethamphetamine Identified in Human Urine After Ecstasy Ingestion. Drug Metabolism and Disposition, 2009, 37, 1448-1455.	3.3	30
38	Activation of the methylation cycle in cells reprogrammed into a stem cell-like state. Oncoscience, 2016, 2, 958-967.	2.2	30
39	A multiscale model of epigenetic heterogeneity-driven cell fate decision-making. PLoS Computational Biology, 2019, 15, e1006592.	3.2	28
40	Epigenetics and nutrition-related epidemics of metabolic diseases: Current perspectives and challenges. Food and Chemical Toxicology, 2016, 96, 191-204.	3.6	27
41	The extra virgin olive oil phenolic oleacein is a dual substrate-inhibitor of catechol-O-methyltransferase. Food and Chemical Toxicology, 2019, 128, 35-45.	3.6	27
42	Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A. Nutrients, 2019, 11, 1656.	4.1	26
43	Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based â€œstarvationâ€•strategies in BRCA1 carriers. Oncotarget, 2016, 7, 52974-52992.	1.8	26
44	Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties. Cell Cycle, 2015, 14, 3527-3532.	2.6	25
45	Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients. Aging, 2019, 11, 2874-2888.	3.1	25
46	Epigenetic regulation of cell fate reprogramming in aging and disease: A predictive computational model. PLoS Computational Biology, 2018, 14, e1006052.	3.2	23
47	Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer. Cancers, 2021, 13, 1132.	3.7	22
48	Silibinin administration improves hepatic failure due to extensive liver infiltration in a breast cancer patient. Anticancer Research, 2014, 34, 4323-7.	1.1	21
49	Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab. Cell Cycle, 2017, 16, 1022-1028.	2.6	19
50	Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 7661.	4.1	19
51	Metformin Potentiates the Benefits of Dietary Restraint: A Metabolomic Study. International Journal of Molecular Sciences, 2017, 18, 2263.	4.1	18
52	The influence of 5-HTT and COMT genotypes on verbal fluency in ecstasy users. Journal of Psychopharmacology, 2010, 24, 1381-1393.	4.0	17
53	Metformin targets histone acetylation in cancer-prone epithelial cells. Cell Cycle, 2016, 15, 3355-3361.	2.6	17
54	Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy. Cancers, 2020, 12, 1757.	3.7	17

#	Article	IF	Citations
55	Revisiting silibinin as a novobiocin-like Hsp90â€¯C-terminal inhibitor: Computational modeling and experimental validation. Food and Chemical Toxicology, 2019, 132, 110645.	3.6	16
56	Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer. Oncotarget, 2016, 7, 82185-82199.	1.8	16
57	Mitostemness. Cell Cycle, 2018, 17, 918-926.	2.6	15
58	Computational de-orphanization of the olive oil biophenol oleacein: Discovery of new metabolic and epigenetic targets. Food and Chemical Toxicology, 2019, 131, 110529.	3.6	15
59	Metformin Is a Pyridoxal-5â€²-phosphate (PLP)-Competitive Inhibitor of SHMT2. Cancers, 2021, 13, 4009.	3.7	15
60	Xenopatients 2.0: Reprogramming the epigenetic landscapes of patient-derived cancer genomes. Cell Cycle, 2014, 13, 358-370.	2.6	14
61	An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors. Carcinogenesis, 2019, 40, 27-40.	2.8	14
62	Lung Cancer Management with Silibinin: A Historical and Translational Perspective. Pharmaceuticals, 2021, 14, 559.	3.8	14
63	Discovery and validation of an INflammatory PROtein-driven GAstric cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics. Oncotarget, 2014, 5, 1942-1954.	1.8	14
64	Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer. Journal of Clinical Medicine, 2019, 8, 2180.	2.4	12
65	BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells. Oncotarget, 2017, 8, 35019-35032.	1.8	12
66	EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells. Oncology Reports, 2017, 38, 263-270.	2.6	11
67	Active transmembrane drug transport in microgravity: a validation study using an ABC transporter model. F1000Research, 2014, 3, 201.	1.6	10
68	Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity. Oncotarget, 2017, 8, 99223-99236.	1.8	9
69	Accelerated geroncogenesis in hereditary breast-ovarian cancer syndrome. Oncotarget, 2016, 7, 11959-11971.	1.8	9
70	Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer. Cancers, 2021, 13, 4168.	3.7	8
71	Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 7737.	4.1	6
72	Progesterone receptor isoform-dependent cross-talk between prolactin and fatty acid synthase in breast cancer. Aging, 2020, 12, 24671-24692.	3.1	6

#	Article	IF	Citations
73	Metformin: Targeting the Metabolo-Epigenetic Link in Cancer Biology. Frontiers in Oncology, 2020, 10, 620641.	2.8	5
74	In silico clinical trials for anti-aging therapies. Aging, 2019, 11, 6591-6601.	3.1	3
75	Mimetics of extra virgin olive oil phenols with anti-cancer stem cell activity. Aging, 2020, 12, 21057-21075.	3.1	2
76	Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin. Pharmaceuticals, 2022, 15, 19.	3.8	2
77	Genetics of Ecstasy (MDMA) Use. , 2013, , 441-451.		1